TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India
Brief Summary: People from the Indian subcontinent are more likely to get diabetes, even at younger ages. The Diabetes Community Lifestyle Improvement Program (D-CLIP) will test in a randomized trial if a culturally specific, community-based lifestyle and metformin (for individuals who do not respond to lifestyle change alone) intervention for men and women living in Chennai, India can effectively prevent type 2 diabetes in high-risk individuals. Lifestyle interventions are programs that seek to prevent disease by promoting changes in health behaviors, improved diet, increased physical activity, and weight loss. The results of this program will be used to make policy and public health recommendations, which will result in broader diabetes prevention efforts. The research team hypothesizes that this program will result in improvements in health (diabetes prevention, weight loss, and improvements in other markers of chronic disease) for intervention participants compared to participants in the control arm of the study.


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Virtual Coach software | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Activity monitor and website | Intervention Type: OTHER; Name: Virtual Coach software; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Activity monitor and website; Assigned to Arm(s): Control
C: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
D: Intervention Type: BEHAVIORAL; Name: Exercise and diet - based on DPS and DPP; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India
Brief Summary: People from the Indian subcontinent are more likely to get diabetes, even at younger ages. The Diabetes Community Lifestyle Improvement Program (D-CLIP) will test in a randomized trial if a culturally specific, community-based lifestyle and metformin (for individuals who do not respond to lifestyle change alone) intervention for men and women living in Chennai, India can effectively prevent type 2 diabetes in high-risk individuals. Lifestyle interventions are programs that seek to prevent disease by promoting changes in health behaviors, improved diet, increased physical activity, and weight loss. The results of this program will be used to make policy and public health recommendations, which will result in broader diabetes prevention efforts. The research team hypothesizes that this program will result in improvements in health (diabetes prevention, weight loss, and improvements in other markers of chronic disease) for intervention participants compared to participants in the control arm of the study.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Promote and support healthy behaviors | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Promote and support healthy behaviors; Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
C: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Intervention Type: BEHAVIORAL; Name: diet- and exercise intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Gestational Diabetes Mellitus Using a Home-based Supervised Exercise Program During Pregnancy
Brief Summary: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy and has serious health implications for both the pregnant woman and her child. In particular, offspring of mothers with GDM have an increased prevalence of obesity, diabetes and metabolic syndrome, perpetuating serious health consequences in subsequent generations.

Although regular exercise offers numerous benefits for both the mother and her child, its effectiveness in preventing GDM remains to be established. It has been recently shown that regular supervised home-based exercise may attenuate the decline in glucose tolerance in obese pregnant women. This study aims to conduct a single-centred, multi-sited, single-blinded randomised controlled trial examining the effect of 14 weeks of supervised home-based exercise (commenced at 14 weeks gestation) on the recurrence and severity of GDM, along with other aspects of maternal and fetal wellbeing.

Eligible participants (n = 200) will be randomly allocated to an exercise intervention (n = 100) or a control group (n = 100). The exercise intervention will involve three 60-minute home-based, supervised exercise sessions each week. This type of program overcomes many of the barriers to exercise in this population including transportation, child care issues and embarrassment associated with exercising in a public venue. The investigators have already shown this program to be both feasible and warmly accepted by obese pregnant women.


Options:
A: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet and exercise counseling | Arm Label: Control, just measurements; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diet and exercise counseling; Assigned to Arm(s): Lifestyle counseling
B: N/A
C: Arm Label: Control group; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with overweight; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with obesity; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with gestational diabetes; Type: N/A; Interventions: N/A
D: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised home-based exercise | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised home-based exercise; Assigned to Arm(s): Exercise group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Open Label, Trial Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Settings
Brief Summary: The World Health Organization and UNAIDS cite that male circumcision can reduce the lifetime risk of HIV infection by 60% in high risk areas such as Sub Saharan Africa.

Rwanda has a national plan to offer a voluntary circumcision program to 2 million adult men in 2 years as part of a comprehensive HIV prevention package. To achieve this goal, the government is continuing to study the PrePex™ device, developed to enable rapid adult male circumcision in resource limited settings.

The study will enroll one hundred and fifty (150) persons scheduled for voluntary circumcision. The subjects will be randomly divided into two unbalanced study arms, PrePex™ arm which will include about a hundred and twenty (100) subjects and surgical circumcision arm which will include about sixty (50) subjects.

Study duration per subject will be 9 weeks.


Options:
A: Arm Label: Unicirc with tissue adhesive; Type: EXPERIMENTAL; Interventions: Procedure: Unicirc with tissue adhesive | Arm Label: Open Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Surgical | Intervention Type: PROCEDURE; Name: Unicirc with tissue adhesive; Assigned to Arm(s): Unicirc with tissue adhesive | Intervention Type: PROCEDURE; Name: Open Surgical; Assigned to Arm(s): Open Surgical
B: Arm Label: PrePex™; Type: EXPERIMENTAL; Interventions: Device: PrePex™ device for adult male circumcision | Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical circumcision | Intervention Type: DEVICE; Name: PrePex™ device for adult male circumcision; Assigned to Arm(s): PrePex™ | Intervention Type: PROCEDURE; Name: Surgical circumcision; Assigned to Arm(s): Surgical
C: Arm Label: Circumcised immediately; Type: ACTIVE_COMPARATOR; Interventions: Procedure: male circumcision | Arm Label: Delayed Circumcision; Type: PLACEBO_COMPARATOR; Interventions: Procedure: male circumcision | Intervention Type: PROCEDURE; Name: male circumcision; Assigned to Arm(s): Circumcised immediately, Delayed Circumcision
D: Arm Label: PrePex™ device; Type: EXPERIMENTAL; Interventions: Device: PrePex™ device for adult male circumcision | Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical circumcision | Intervention Type: DEVICE; Name: PrePex™ device for adult male circumcision; Assigned to Arm(s): PrePex™ device | Intervention Type: PROCEDURE; Name: Surgical circumcision; Assigned to Arm(s): Surgical

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: User Preference Study to Compare a 40cm Intermittent Catheter to a 30cm Intermittent Catheter
Brief Summary: This is an unblinded, multi-center, randomized, controlled, cross-over study assessing wheel-chair bound, male user preference and catheter characteristics of two intermittent urinary catheters. Subjects enrolled in the study will be randomized to order of catheter use. Individual participation will consist of approximately 1 week of product use. The null hypothesis to be tested is there no difference between catheters.


Options:
A: Arm Label: Compact catheter; Type: EXPERIMENTAL; Interventions: Device: SpeediCath Compact | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: SpeediCath Compact; Assigned to Arm(s): Compact catheter | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: Single-use catheter; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-use catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with 0.5% benzalkonium chloride; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with soap and water; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Intervention Type: PROCEDURE; Name: Single-use catheter; Assigned to Arm(s): Single-use catheter | Intervention Type: PROCEDURE; Name: Reused catheter; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water | Intervention Type: DIAGNOSTIC_TEST; Name: Urine culture; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water, Single-use catheter
C: Arm Label: SpeediCath catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: SpeediCath | Arm Label: Test product; Type: EXPERIMENTAL; Interventions: Device: Test Catheter - SpeediCath Compact Male | Intervention Type: DEVICE; Name: Test Catheter - SpeediCath Compact Male; Assigned to Arm(s): Test product | Intervention Type: DEVICE; Name: SpeediCath; Assigned to Arm(s): SpeediCath catheter
D: Arm Label: 30 cm Intermittent Catheter; Type: EXPERIMENTAL; Interventions: Device: 30 cm Intermittent Catheter | Arm Label: 40 cm Intermittent Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: 40 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 30 cm Intermittent Catheter; Assigned to Arm(s): 30 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 40 cm Intermittent Catheter; Assigned to Arm(s): 40 cm Intermittent Catheter

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Moderate Dose Hydrocortisone in Treatment of Severe Sepsis and Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome: A Randomized Controlled Trial
Brief Summary: Severe sepsis/septic shock is a serious condition associated with high mortality rate. Hydrocortisone has been recommended as a useful treatment to decrease mortality in hemodynamically unstable septic shock patients, not response to fluid and moderate dose of vasopressor. During the progression of severe sepsis/septic shock, multi-organ dysfunction can develop. Acute lung injury (ALI) and its more severe form, acute respiratory syndrome (ARDS) is one of the common organ dysfunction associated with septic shock. Information from a meta-analysis suggested that moderate dose of hydrocortisone may improve the ARDS patients' outcome. Whether hydrocortisone can effectively prevent disease progression and death in severe sepsis/septic shock patients who complicated with ALI/ARDS has not been proven.


Options:
A: Arm Label: Experimental Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (0.9%) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Experimental Group | Intervention Type: DRUG; Name: Normal Saline (0.9%); Assigned to Arm(s): Placebo Group
B: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
D: Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: Sterile air filled vial; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile air filled vial | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Sterile air filled vial; Assigned to Arm(s): Sterile air filled vial

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Moderate Dose Hydrocortisone in Treatment of Severe Sepsis and Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome: A Randomized Controlled Trial
Brief Summary: Severe sepsis/septic shock is a serious condition associated with high mortality rate. Hydrocortisone has been recommended as a useful treatment to decrease mortality in hemodynamically unstable septic shock patients, not response to fluid and moderate dose of vasopressor. During the progression of severe sepsis/septic shock, multi-organ dysfunction can develop. Acute lung injury (ALI) and its more severe form, acute respiratory syndrome (ARDS) is one of the common organ dysfunction associated with septic shock. Information from a meta-analysis suggested that moderate dose of hydrocortisone may improve the ARDS patients' outcome. Whether hydrocortisone can effectively prevent disease progression and death in severe sepsis/septic shock patients who complicated with ALI/ARDS has not been proven.


Options:
A: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
B: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Feasibility of Delivering Xenon to Patients Before and After Coronary Artery Bypass Graft Implantation: a Pilot Study
Brief Summary: The aim of this study is to determine whether xenon - as compared to sevoflurane - can be applied safely in patients for general anesthesia before and after CABG implantation.


Options:
A: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane
B: Arm Label: CytoSorb; Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): CytoSorb
C: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Device: hemoadsorber for removal of cytokines | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: hemoadsorber for removal of cytokines; Assigned to Arm(s): Interventional group
D: Arm Label: Study (CytoSorb); Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Corticosteroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): Study (CytoSorb) | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Feasibility of Delivering Xenon to Patients Before and After Coronary Artery Bypass Graft Implantation: a Pilot Study
Brief Summary: The aim of this study is to determine whether xenon - as compared to sevoflurane - can be applied safely in patients for general anesthesia before and after CABG implantation.


Options:
A: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
B: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
D: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Benralizumab (Medi-563); Type: EXPERIMENTAL; Interventions: Drug: Benralizumab (Medi-563) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab (Medi-563); Assigned to Arm(s): Benralizumab (Medi-563) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Reslizumab; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: IMA-026 | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: IMA-026; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B

Answer: A